In this issue of Current Oncology
Curr. Oncol. 2011, 18(3), 99; https://doi.org/10.3390/curroncol18030002
Submission received: 3 May 2011
/
Accepted: 9 May 2011
/
Published: 1 June 2011
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
In women with early-stage breast cancer, the use of fec-d (5-fluorouracil–epirubicin–cyclophosphamide followed by docetaxel) has increased, given the increased efficacy of that regimen compared with fec-100 (5-fluorouracil–epirubicin–cyclophosphamide).[...]
Share and Cite
MDPI and ACS Style
McLean, M. In this issue of Current Oncology. Curr. Oncol. 2011, 18, 99. https://doi.org/10.3390/curroncol18030002
AMA Style
McLean M. In this issue of Current Oncology. Current Oncology. 2011; 18(3):99. https://doi.org/10.3390/curroncol18030002
Chicago/Turabian StyleMcLean, M. 2011. "In this issue of Current Oncology" Current Oncology 18, no. 3: 99. https://doi.org/10.3390/curroncol18030002
APA StyleMcLean, M. (2011). In this issue of Current Oncology. Current Oncology, 18(3), 99. https://doi.org/10.3390/curroncol18030002
